Apmonia Therapeutics’ technology platform, specialized in the therapeutic targeting of the extracellular matrix, shows strong potential in the field of cardiovascular pathologies and thrombosis
Reims, December 6, 2022 – Apmonia Therapeutics, a biotechnology company developing new therapeutic strategies based on peptide approaches with therapeutic applications – in particular in the field of oncology – announces today the launch of a research and development program supported by the French National Research Agency (ANR). The THROMBOTAX program, selected in the context of the « AAPG 2022 – Biomedical Innovation » call for projects, is based on the creation of an industrial-academic consortium whose objective will be to validate the therapeutic targeting of the TSP-1/CD47 axis in the field of arterial thrombotic pathologies.
This collaboration is based on Apmonia Therapeutics’ technological platform dedicated to the targeting of the extracellular matrix via peptide approaches on the one hand, and on the expertise of the joint research units CNRS – University of Reims Champagne-Ardenne 7369 (MEDyC, Reims), specializing in the study of the remodeling of the extracellular matrix, and INSERM – University of Lorraine UMRS 1116 (DCAC, Nancy), which is working on acute and chronic cardiovascular failures, on the other hand.
Peptides that antagonize the binding between thrombospondin-1 (TSP-1) and its membrane receptor CD47 result in controlling platelet activation in cardiovascular and thrombotic diseases. This original approach represents a new class of antithrombotic molecules, particularly for the treatment of ischemic lesions.
“The support of the ANR is a recognition of the quality of our research and underlines the relevance and therapeutic potential of the peptide approach on which we have already made significant advances in oncology,” saysDr. Albin Jeanne, President of Apmonia Therapeutics. “We are very pleased with the interest generated by our expertise in the therapeutic targeting of extracellular matrix components and by our technology platform.”
“The recognition of the ANR has perpetuated this consortium whose quality and complementarity will allow to approach the scientific hypothesis at all levels, from the mechanism of action to the translational aspects” notes Dr. Patrick Lacolley, INSERM Research Director and Director of the joint INSERM – University of Lorraine UMRS 1116 unit. “Being able to rely on the scientific expertise and technological know-how of Apmonia Therapeutics has been decisive and is definitely a major asset that will allow us to expect significant benefits in terms of biomedical innovation.”
About Apmonia Therapeutics:
Apmonia Therapeutics is a biotechnology company developing innovative therapeutic strategies based on the targeting of the extracellular matrix. Leveraging recent advances in computational protein and peptide engineering, as well as state-of-the-art screeningand validation technologies, Apmonia Therapeutics’ platform technology is focused on developing novel therapies for cancer patients.
About UMR CNRS – URCA 7369:
Extracellular Matrix and Cellular Dynamics (MEDyC) research unit uses multidisciplinary and multiscale approaches to decipher the mechanisms governing the remodeling processes of the extracellular matrix. In particular, MEDyC has acquired expertise in the development of tools and methods to identify and characterize biomarkers and therapeutic targets associated with the pathological microenvironment, especially in metabolic and vascular diseases such as thrombosis and atherosclerosis.
About INSERM – UL UMR S 1116:
Acute and Chronic Cardiovascular Deficiency research unit (DCAC) is a leader in clinical research (aging, heart failure, acquired chronic inflammatory vascular diseases and sepsis) and experimental research in mechanotransduction (arterial stiffness), thrombophilia and immuno-inflammatory diseases.
Press contact:
Agency Acorelis – Gilles Petitot – 0033 6 20 27 65 94 – gilles.petitot@acorelis.com
Apmonia Therapeutics – 0033 6 91 89 83 – contact@apmonia-therapeutics.com